Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 2/20 | 0.81 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.69 |
| ▸ | TP53 | P04637 | 4/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.69 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 7/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | KIF11 | P52732 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzidine SCHEMBL11211665 | 1.00 | ACHE (0.81) | ACHEALDH1A1TDP1TP53CYP3A4 | |
| SCHEMBL2608098 | 1.00 | ACHE (0.81) | ACHEALDH1A1TDP1TP53CYP3A4 | |
| SCHEMBL23252415 | 0.92 | ACHE (0.68) | ACHEALDH1A1TDP1TP53CYP3A4 | |
| SCHEMBL16716051 | 0.92 | ACHE (0.68) | ACHEALDH1A1TDP1TP53CYP3A4 | |
| SCHEMBL12386341 | 0.92 | ACHE (0.68) | ACHEALDH1A1TDP1TP53CYP3A4 | |
| SCHEMBL11887 | 0.90 | — | — | |
| SCHEMBL8469646 | 0.90 | ACHE (1.00) | ACHEALDH1A1TDP1TP53CYP3A4 | |
| Benzidine SCHEMBL28531320 | 0.87 | ACHE (0.62) | ACHEALDH1A1TDP1TP53CYP3A4 | |
| SCHEMBL1439188 | 0.87 | — | — | |
| SCHEMBL6463424 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 377 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107459535-A | Polysubstituted quinoline coordinated iridium hybrid compound and preparation method and application thereof | 南京工业大学 | 2017-12-12 | — | — | CN | claimed |
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2026-03-31 | — | — | US | disclosed |
| US-20250289781-A1 | TRIFLUOROMETHANESULFONYLATING AGENT COMPOSITION AND METHOD FOR PRODUCING TRIFLUOROMETHANESULFONYLOXY COMPOUND OR TRIFLUOROMETHANESULFONYL COMPOUND | CENTRAL GLASS COMPANY, LIMITED (JP) | 2025-09-18 | — | — | US | disclosed |
| EP-4308628-B1 | ALKYD RESIN, COATING COMPOSITION, AND SUBSTRATE COATED WITH SUCH COATING COMPOSITON | AKZO NOBEL COATINGS INT BV (NL) | 2025-04-30 | — | — | EP | disclosed |
| CN-113727972-B | Novel hydrazone derivatives having terminal amine groups substituted with aryl or heteroaryl groups and use thereof | 韩国科学技术研究院 | 2024-12-27 | — | — | CN | disclosed |
| CN-119137096-A | Trifluoromethanesulfonyl a composition of the agent trifluoromethanesulfonyl oxy compounds or Process for producing trifluoromethanesulfonyl compound | 中央硝子株式会社 | 2024-12-13 | — | — | CN | disclosed |
| US-12054582-B2 | Alkyd resin, coating composition, and substrate coated with such coating composition | AKZO NOBEL COATINGS INTERNATIONAL B.V. (NL) | 2024-08-06 | — | — | US | disclosed |
| CN-117098795-B | Alkyd resin, coating composition and substrate coated with the coating composition | 阿克佐 诺贝尔国际涂料股份有限公司 | 2024-07-19 | — | — | CN | disclosed |
| EP-4400559-A1 | LIGHT-EMITTING DEVICE INCLUDING ORGANOMETALLIC COMPOUND, ELECTRONIC APPARATUS INCLUDING THE LIGHT-EMITTING DEVICE, AND THE ORGANOMETALLIC COMPOUND | Samsung Display Co., Ltd. (KR) | 2024-07-17 | — | — | EP | disclosed |
| EP-4395499-A1 | LIGHT-EMITTING DEVICE AND ELECTRONIC APPARATUS INCLUDING THE SAME | Samsung Electronics Co., Ltd. (KR) | 2024-07-03 | — | — | EP | disclosed |
| US-5877278-A | SOLID PHASE SYNTHESIS USING TWO SUBMONOMERS-AN ACYLATING AGENT, E.G. A HALOACETIC ACID, AND A PRIMARY AMINE; CYCLIZATION TO PRODUCE MIMETICS OF DRUGS; ELIMINATION OF THE NECESSITY OF PROTECTION GROUPS | CHIRON CORPORATION (US) | 1999-03-02 | — | — | US | disclosed |
| US-5831005-A | ACYLATION, NUCLEOPHILIC DISPLACEMENT CYCLES | CHIRON CORPORATION (US) | 1998-11-03 | — | — | US | disclosed |
| EP-0789577-A4 | SYNTHESIS OF N-SUBSTITUTED OLIGOMERS | CHIRON CORP (US) | 1998-07-22 | — | — | EP | disclosed |
| EP-0805143-A1 | ORGANIC ELECTROLUMINESCENT ELEMENT, ORGANIC THIN FILM, AND TRIAMINE COMPOUNDS | IDEMITSU KOSAN COMPANY LIMITED (JP) | 1997-11-05 | — | — | EP | disclosed |
| EP-0789577-A1 | SYNTHESIS OF N-SUBSTITUTED OLIGOMERS | CHIRON CORPORATION (US) | 1997-08-20 | — | — | EP | disclosed |
| WO-1996040202-A1 | SYNTHESIS OF N-SUBSTITUTED OLIGOMERS | CHIRON CORPORATION (US) | 1996-12-19 | — | — | WO | disclosed |
| US-5480871-A | TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | CHIRON CORPORATION (US) | 1996-01-02 | — | — | US | disclosed |
| US-5447916-A | Hypotensive agents | CHIRON CORPORATION (US) | 1995-09-05 | — | — | US | disclosed |
| WO-1995004072-A1 | PEPTOID ALPHA-1 ADRENERGIC RECEPTOR LIGANDS | CHIRON CORPORATION (US) | 1995-02-09 | — | — | WO | disclosed |
| WO-1995001334-A1 | ARYLAMINE-DERIVED INDOLE COMPOUNDS AS SELECTIVE 5HT1D AND 5HT1B RECEPTOR LIGANDS | PIERRE FABRE MEDICAMENT (FR) | 1995-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250289781-A1 | TRIFLUOROMETHANESULFONYLATING AGENT COMPOSITION AND METHOD FOR PRODUCING TRIFLUOROMETHANESULFONYLOXY COMPOUND OR TRIFLUOROMETHANESULFONYL COMPOUND | AFF1, BRAF, AFF2 | ACHE 3266/4885ALDH1A1 2621/4885TDP1 1156/4885 |
| US-12590071-B2 | Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof | ABL1, TH, CYP3A43 | ACHE 3315/4885ALDH1A1 1008/4885TDP1 2058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.